At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMRA Imara Inc.
Pre-Market Trading 11-05 08:50:42 EST
25.28
+0.00
0.00%
High25.28
Low25.28
Vol0.00
Open25.28
D1 Closing25.28
Amplitude0.00%
Mkt Cap165.80M
Tradable Cap49.81M
Total Shares6.56M
T/O1.60M
T/O Rate0.00%
Tradable Shares1.97M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Press Release: Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.